Drugs / sotrastaurin
sotrastaurin
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02273219 | Nov 2014 → Oct 2017 | uveal melanoma | Columbia University | Completed | No outcome recorded |
| Phase 1 | NCT01854606 | Dec 2013 → Jun 2016 | diffuse large B-cell lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01430416 | Dec 2011 → May 2019 | uveal melanoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01402440 | Nov 2011 → Apr 2014 | diffuse large B-cell lymphoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT01594255 | Jul → Sep 2009 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00545259 | Oct 2007 → Feb 2009 | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00416546 | Oct 2006 → Oct 2007 | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00409929 | Jun → Jul 2006 | — | Novartis | Completed | No outcome recorded |
| Phase 1/23 trials · 1 missed | ||||||
| Phase 1/2 | NCT01801358 | Aug 2013 → May 2015 | uveal melanoma | Array BioPharma | Terminated | No outcome recorded |
| Phase 1/2 | NCT00492869 | Jan 2007 → May 2008 | — | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 1/2 | NCT00403416 | Oct 2006 → May 2008 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT02285244 | Mar 2015 | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, prolymphocytic leukemia | James Blachly | Withdrawn | No outcome recorded |
| Phase 2 | NCT00572585 | Apr 2010 → Apr 2012 | ulcerative colitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01128335 | Apr 2010 → Jul 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01064791 | Dec 2009 → Aug 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00885196 | Apr 2009 → Aug 2011 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00820911 | Sep 2008 → Jul 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00615693 | Jul 2008 → Oct 2009 | panuveitis, posterior uveitis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00555789 | Oct 2007 → Mar 2008 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00504543 Comparator | Jul 2007 → Apr 2011 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sotrastaurin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01128335 ↗ |
| Known as | AEB071 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00409929 ↗ |
| Known as | NVP-AEB071 | ChEMBL registry synonym — accepted as the source's own label CHEMBL565612 ↗ |
| Known as | sotrastaurin acetate | “To determine the objective clinical response rate of AEB071 (sotrastaurin acetate) treatment in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small...” NCT02285244 ↗ |
| Known as | Sotrastaurina | ChEMBL registry synonym — accepted as the source's own label CHEMBL565612 ↗ |
| Known as | Sotrastaurine | ChEMBL registry synonym — accepted as the source's own label CHEMBL565612 ↗ |
| Known as | STN | “Efficacy and safety of protein kinase C inhibitor sotrastaurin (STN) with tacrolimus (TAC)” PMID 25677074 ↗ Feb 2015 |
| Action | Inhibit | “inhibiting protein-kinase C” PMID 21564523 ↗ May 2011 |
| Modality | Small molecule | “a novel small molecule inhibiting protein-kinase C” PMID 21564523 ↗ May 2011 |
| Route | Oral | “ascending single oral doses greater than 500 mg of AEB071” NCT00409929 ↗ |